Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
2000 1
2003 18
2004 31
2005 30
2006 50
2007 205
2008 391
2009 424
2010 440
2011 440
2012 389
2013 353
2014 316
2015 306
2016 305
2017 287
2018 236
2019 104
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

3,676 results
Results by year
Filters applied: . Clear all
Page 1
Antitumoral Potential of Snake Venom Phospholipases A2 and Synthetic Peptides.
Sobrinho JC, et al. Curr Pharm Biotechnol 2016 - Review. PMID 27604356
One of the most widely studied venom components are phospholipases A2. Snake venom phospholipases A2 (svPLA2s) comprise a large class of molecules that catalyze the hydrolysis of the sn-2 position of phospholipids releasing fatty acids and lysophospholipids and are related to a broad spectrum of biotechnological activities. ...
One of the most widely studied venom components are phospholipases A2. Snake venom phospholipases A2 (svPLA2s) c …
Cytosolic phospholipase A₂: physiological function and role in disease.
Leslie CC. J Lipid Res 2015 - Review. PMID 25838312 Free PMC article.
The group IV phospholipase A2 (PLA2) family is comprised of six intracellular enzymes (GIVA, -B, -C, -D, -E, and -F) commonly referred to as cytosolic PLA2 (cPLA2)α, -β, -γ, -δ, -ε, and -ζ. ...With the exception of cPLA2α, the focus of this review, little is known about the in vivo function of group IV enzymes. cPLA2α catalyzes the hydrolysis of phospholipids to arachidonic acid and lysophospholipids that are precursors of numerous bioactive lipids. ...
The group IV phospholipase A2 (PLA2) family is comprised of six intracellular enzymes (GIVA, -B, -C, -D, -E, and -F) commonly …
An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases.
Law SH, et al. Int J Mol Sci 2019 - Review. PMID 30845751 Free PMC article.
LPC is mainly derived from the turnover of phosphatidylcholine (PC) in the circulation by phospholipase A₂ (PLA₂). In the presence of Acyl-CoA, lysophosphatidylcholine acyltransferase (LPCAT) converts LPC to PC, which rapidly gets recycled by the Lands cycle. ...In conclusion, understanding enzyme kinetics and LPC metabolism may help identify novel therapeutic targets in LPC-associated diseases....
LPC is mainly derived from the turnover of phosphatidylcholine (PC) in the circulation by phospholipase A₂ (PLA₂). In the presence of …
Phospholipase A(2) catalysis and lipid mediator lipidomics.
Mouchlis VD and Dennis EA. Biochim Biophys Acta Mol Cell Biol Lipids 2019 - Review. PMID 30905345 Free PMC article.
Phospholipase A(2) (PLA(2)) enzymes are the upstream regulators of the eicosanoid pathway liberating free arachidonic acid from the sn-2 position of membrane phospholipids. ...
Phospholipase A(2) (PLA(2)) enzymes are the upstream regulators of the eicosanoid pathway liberating free arachidonic acid from the s
Lp-PLA2, a new biomarker of vascular disorders in metabolic diseases
De Stefano A, et al. Int J Immunopathol Pharmacol 2019 - Review. PMID 30706739 Free PMC article.
The determination of new and specific blood biomarkers of vascular inflammation associated with obesity-related metabolic syndrome (MetS) and diabetes such as lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) could be useful to identify subject with high risk of cardiovascular events. ...
The determination of new and specific blood biomarkers of vascular inflammation associated with obesity-related metabolic syndrome (MetS) an …
Secreted phospholipases A2 in cancer: diverse mechanisms of action.
Brglez V, et al. Biochimie 2014. PMID 25286228
Secreted phospholipases A2 (sPLA2s) hydrolyse cell and lipoprotein phospholipid membranes to release free fatty acids and lysophospholipids, and can also bind to specific proteins. ...Finally, recent studies have implicated sPLA2s in the regulation of basal lipid metabolism, opening a new window to the understanding of the diverse roles of sPLA2s in cancer. ...
Secreted phospholipases A2 (sPLA2s) hydrolyse cell and lipoprotein phospholipid membranes to release free fatty acids a …
Plant phospholipases A2: perspectives on biotechnological applications.
Mansfeld J. Biotechnol Lett 2009 - Review. PMID 19479320
The secreted phospholipases A(2), representing one type of phospholipases A(2) occurring in plants, show distinct differences in substrate specificities with respect to headgroup and acyl chains of the glycerophospholipids in comparison to their counterparts from animal sources. The other type of phospholipases A(2) in plants, the patatin-related phospholipases A(2), is characterized by broad substrate specificity. ...
The secreted phospholipases A(2), representing one type of phospholipases A(2) occurring in plants, show distinct differences …
Lysosomal phospholipase A2.
Shayman JA and Tesmer JJG. Biochim Biophys Acta Mol Cell Biol Lipids 2019 - Review. PMID 30077006 Free PMC article.
Lysosomal phospholipase A2 (PLA2G15) is a ubiquitous enzyme uniquely characterized by a subcellular localization to the lysosome and late endosome. ...This article is part of a Special Issue entitled Novel functions of phospholipase A2 Guest Editors: Makoto Murakami and Gerard Lambeau....
Lysosomal phospholipase A2 (PLA2G15) is a ubiquitous enzyme uniquely characterized by a subcellular localization to the lysoso …
Calcium-independent phospholipases A2 in murine osteoblastic cells and their inhibition by bromoenol lactone: impact on arachidonate dynamics and prostaglandin synthesis.
Leis HJ and Windischhofer W. J Enzyme Inhib Med Chem 2016. PMID 26609885
CONTEXT: Bromoenol lactone (BEL) is an inhibitor of group VI phospholipases (iPLA2s), but has been shown to have severe side effects. ...Arachidonate (AA) reacylation into phospholipids, inhibitor reaction products, PGHS-1 modification proteomic analysis: HR-LC-MS/MS. ...
CONTEXT: Bromoenol lactone (BEL) is an inhibitor of group VI phospholipases (iPLA2s), but has been shown to have severe side effects. …
Identification of PRDX6 as a regulator of ferroptosis
Lu B, et al. Acta Pharmacol Sin 2019. PMID 31036877 Free PMC article.
More importantly, the application of a specific PRDX6 phospholipase A2 (iPLA2) inhibitor, MJ-33, synergistically enhances the ferroptosis induced by Erastin, suggesting that PRDX6 removes LOOH through its iPLA2 activity. ...
More importantly, the application of a specific PRDX6 phospholipase A2 (iPLA2) inhibitor, MJ-33, synergistically enhances the …
3,676 results
Jump to page
Feedback